Performance status of patients is the major prognostic factor at all stages of pancreatic cancer.

TAŞ F., Sen F., Odabas H., Kilic L., Keskin S., YILDIZ İ.

International journal of clinical oncology, cilt.18, sa.5, ss.839-46, 2013 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 18 Sayı: 5
  • Basım Tarihi: 2013
  • Doi Numarası: 10.1007/s10147-012-0474-9
  • Dergi Adı: International journal of clinical oncology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.839-46
  • Anahtar Kelimeler: Pancreatic cancer, Performance status, Prognosis, Survival, PHASE-III TRIAL, GEMCITABINE, SURVIVAL, ADENOCARCINOMA, RESECTION, CHEMOTHERAPY, CA-19-9, METASTASIS, CARCINOMA
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

The aim of this study was to identify and evaluate the clinicopathologic factors and to elucidate the clinical importance of performance status on the outcome of patients with pancreatic cancer.